GlassScriptPhysician profile
Steven Daniel Hochman
NPI 1730566191
$118,695.20
in general payments reported to CMS, 2019-2025
6 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.11 · 2021: $18.00 · 2022: $43.88 · 2023: $6,247 · 2024: $52K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Honoraria: $38K · Travel and Lodging: $21K · Food and Beverage: $3,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,362.00 |
| Honoraria | $38,350.00 |
| Travel and Lodging | $21,089.60 |
| Food and Beverage | $3,817.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $68,448.80 | 2021-2025 | Epclusa, Biktarvy |
| Braeburn INC. | $50,039.71 | 2023-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $153.88 | 2024 | Invega Sustenna, Invega Trinza |
| Janssen Biotech, INC. | $19.80 | 2023 | Symtuza |
| Indivior INC. | $18.90 | 2023 | Sublocade |
| Alkermes, INC. | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hochman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.